Related Experiment Video

Updated: Dec 31, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.3K

The Impact of CYP24A1 Polymorphisms on Hypertension Susceptibility

Qiuhong Bao1, Dan Wang1, Yong Zhang1

  • 1Gerontological Center, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

Kidney & Blood Pressure Research
|January 10, 2020
PubMed

Insights

Genetic variations in the CYP24A1 gene are linked to hypertension risk. Specific CYP24A1 polymorphisms show protective effects and influence risk based on age and sex in the Chinese population.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Endocrinology

Background:

  • Hypertension is a major global health concern contributing to significant mortality and disability.
  • The CYP24A1 gene, involved in vitamin D metabolism, has been implicated in hypertension, but the role of its genetic variations remains largely uncharacterized.
  • Understanding genetic predispositions to hypertension is crucial for developing targeted prevention and treatment strategies.

Purpose of the Study:

  • To investigate the association between specific genetic variations (polymorphisms) in the CYP24A1 gene and the risk of developing hypertension.
  • To explore potential interactions between CYP24A1 polymorphisms, age, and sex in relation to hypertension susceptibility.
  • To identify specific CYP24A1 variants that may serve as biomarkers for hypertension risk in the Chinese Han population.

Main Methods:

  • A case-control study design was employed, involving 503 patients with hypertension and 498 healthy controls from the Chinese Han population.
  • Genotyping of CYP24A1 polymorphisms was performed using the Agena MassARRAY method.
  • Statistical analyses, including odds ratios (OR) and 95% confidence intervals (CI), were used to evaluate the association between genetic variations and hypertension risk under various genetic models.

Main Results:

  • The CYP24A1 polymorphism rs56229249 was found to significantly decrease hypertension risk in both homozygote and recessive models (OR 0.51, p < 0.05).
  • Stratification analyses revealed that rs2762934 increased hypertension risk in younger individuals (<61 years), while rs1977297 influenced risk in older individuals (≥61 years).
  • Further findings indicated that rs2762940 is associated with hypertension risk in men, and rs56229249 acts as a protective factor in women.

Conclusions:

  • Genetic variations within the CYP24A1 gene are significantly associated with hypertension susceptibility in the Chinese population.
  • Specific CYP24A1 polymorphisms demonstrate differential effects on hypertension risk, influenced by age and sex.
  • These findings highlight the potential role of CYP24A1 in the genetic etiology of hypertension and suggest its utility in risk stratification.
Abstract

Keywords:
CYP24A1Case-control studyGenetic variationsHypertensionRisk

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.1K
Assessing Murine Resistance Artery Function Using Pressure Myography07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

23.0K

Related Concept Videos

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
307
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
567
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
Factors affecting Blood pressure01:28

Factors affecting Blood pressure

Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
6.2K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
395
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
151